about
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatmePharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate renal impairment.Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment.Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trialA phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer
P50
Q27851403-F4C9606D-B982-4F62-8E09-0F301BBACD5BQ33561588-AF9CC433-3333-4E99-8428-43276B8D5581Q33887982-9971254D-6E59-42AD-8591-82B4AD8CE598Q33887987-9ACBD5F9-17E5-4107-8DD8-1E71127A7585Q35584284-DCA6639A-6744-457A-945C-B3B10A4D0883Q37054957-07227308-0D8B-4E1C-8F94-2CC4E5109242Q37117151-6E301F32-9287-4EC3-9633-7C1F477CFE90
P50
description
onderzoeker
@nl
name
Cristina Oliva
@ast
Cristina Oliva
@en
Cristina Oliva
@es
Cristina Oliva
@sl
type
label
Cristina Oliva
@ast
Cristina Oliva
@en
Cristina Oliva
@es
Cristina Oliva
@sl
prefLabel
Cristina Oliva
@ast
Cristina Oliva
@en
Cristina Oliva
@es
Cristina Oliva
@sl